Quick Answer
Relay Therapeutics, Inc. reported Common Stock Shares Outstanding of 173.87 million shares for the year ending 2025.
- Relay Therapeutics, Inc. showed an increase of +3.6% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Relay Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: 4.59 million shares | Q3 2020: 89.80 million shares | Q1 2021: 90.43 million shares | Q2 2021: 92.55 million shares | Q3 2021: 92.80 million shares | Q1 2022: 108.43 million shares | Q2 2022: 108.81 million shares | Q3 2022: 120.81 million shares | Q1 2023: 121.48 million shares | Q2 2023: 121.94 million shares | Q3 2023: 123.16 million shares | Q1 2024: 132.30 million shares | Q2 2024: 133.32 million shares | Q3 2024: 166.89 million shares | Q1 2025: 170.48 million shares | Q2 2025: 171.69 million shares | Q3 2025: 172.63 million shares.
- Over the full 7 years of available data (2019 to 2025), Relay Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 4,206.4%.
- Historical annual values: Fiscal year 2025: 173.87 million shares | Fiscal year 2024: 167.76 million shares | Fiscal year 2023: 127.46 million shares | Fiscal year 2022: 121.11 million shares | Fiscal year 2021: 108.21 million shares | Fiscal year 2020: 89.91 million shares | Fiscal year 2019: 4.04 million shares.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: